RECRUITING
I'm interested ...!!
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Conditions:
🦠 COVID-19
🗓️ Study Start (Actual) 6 July 2021
🗓️ Primary Completion (Estimated) December 2024
✅ Study Completion (Estimated) December 2024
👥 Enrollment (Estimated) 400
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Dallas, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021.
    • * \>18 years old

    Exclusion Criteria:

    • * • Outpatient visit
    • * Not admitted to an inpatient or observation status
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 21 October 2022
  • First Submitted that Met QC Criteria 26 March 2024
  • First Posted 28 March 2024

Study Record Updates

  • Last Update Submitted that Met QC Criteria 26 March 2024
  • Last Update Posted 28 March 2024
  • Last Verified March 2024
I'm interested ...!!